Donald Baker, R.T.(R)(CT)(MR) presented “Prostate Cancer Detection-Integrated Clinical Solution” during the 7th Global Summit on Precision Diagnosis and Treatment of Prostate Cancer on September 22, 2023.
How to cite: Baker, Donald “Prostate Cancer Detection-Integrated Clinical Solution.” September 22, 2023. Accessed Dec 2024. https://grandroundsinurology.com/prostate-cancer-detection-integrated-clinical-solution/
Prostate Cancer Detection-Integrated Clinical Solution – Summary
Donald Baker, R.T.(R)(CT)(MR), discusses the advancements in prostate cancer detection, emphasizing the development and implementation of an integrated clinical solution. This comprehensive approach leverages state-of-the-art imaging technologies, combined with innovative diagnostic protocols, to improve the early detection and characterization of prostate cancer.
Baker discusses the importance of standardized imaging protocols using mpMRI and PET/CT scans to ensure consistency and reliability in prostate cancer detection. The adoption of these standards across clinical settings contributes to better patient management and treatment planning. In addition, Baker emphasizes the integration of artificial intelligence (AI) and machine learning algorithms into the diagnostic workflow.
Baker underscores the significance of multidisciplinary collaboration in the successful implementation of this integrated clinical solution. By bringing together expertise from radiology, urology, oncology, and medical physics, a more holistic approach to prostate cancer detection and management is achieved.
The Global Summit on Precision Diagnosis and Treatment of Prostate Cancer is a unique multi-disciplinary forum organized to inform the key health care stakeholders about the emerging advances in clinical case and research and create a consensus-based vision for the future of precision care and educational and research strategy for its realization. The mission of the Summit is to fill the currently existing gap between the key experts of in vivo imaging, the world authorities in the in vitro fluid- and tissue-based molecular diagnostics, including genomics, and thought leaders in the development of novel observation strategies (e.g., active surveillance, or AS) and therapeutic interventions.
